Reviews in Endocrine & Metabolic Disorders最新文献

Traumatic brain injury and prolactin. 创伤性脑损伤与催乳素

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2024-09-03 DOI: 10.1007/s11154-024-09904-x

Aysa Hacioglu, Fatih Tanriverdi

{"title":"Traumatic brain injury and prolactin.","authors":"Aysa Hacioglu, Fatih Tanriverdi","doi":"10.1007/s11154-024-09904-x","DOIUrl":"https://doi.org/10.1007/s11154-024-09904-x","url":null,"abstract":"Traumatic brain injury (TBI) is a well-known etiologic factor for pituitary dysfunctions, with a prevalence of 15% during long-term follow-up. The most common hormonal disruption is growth hormone deficiency, followed by central adrenal insufficiency, central hypogonadism, and central hypothyroidism in varying order across studies. The prevalence of serum prolactin disturbances ranged widely from 0 to 85%. Prolactin release is mainly regulated by hypothalamic dopamine inhibition, and mediators such as TRH, serotonin, cytokines, and neurotransmitters have modulatory effects. Many factors, such as hypothalamic and/or pituitary gland injuries, as well as fluctuations in dopaminergic activity and other mediators and stress response, may cause derangements in serum prolactin levels after TBI. Although it is challenging to investigate the direct effects of TBI on serum prolactin levels due to many confounders, basal prolactin measurements and stimulation tests provide insight into the functionality of the hypothalamus and pituitary gland after TBI. Moreover, during the acute phase of TBI, prolactin levels appear to correlate with TBI severity. In contrast, in the chronic phase, hypoprolactinemia may function as an indirect indicator of pituitary dysfunction and reduced pituitary volume. Further investigations are needed to elucidate the pathophysiologic mechanisms underlying the prolactin trend following TBI, its significance, and its associations with other pituitary hormone dysfunctions. In this article, we re-evaluated our patients' TBI data regarding prolactin levels during prospective long-term follow-up, and reviewed the literature regarding the prevalence, pathophysiology, and clinical implications of serum prolactin disturbances during acute and chronic phases following TBI.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness and safety of continuous subcutaneous hydrocortisone infusion in managing adrenocortical insufficiency in adult patients: a systematic review. 持续皮下注射氢化可的松治疗成人肾上腺皮质功能不全的有效性和安全性：系统综述。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2024-09-02 DOI: 10.1007/s11154-024-09905-w

Yazeed Alekrish, Mohammed Alotaibi, Aishah Ekhzaimy

{"title":"Effectiveness and safety of continuous subcutaneous hydrocortisone infusion in managing adrenocortical insufficiency in adult patients: a systematic review.","authors":"Yazeed Alekrish, Mohammed Alotaibi, Aishah Ekhzaimy","doi":"10.1007/s11154-024-09905-w","DOIUrl":"https://doi.org/10.1007/s11154-024-09905-w","url":null,"abstract":"Oral hormone replacement therapy has been and continues to be the cornerstone of adrenocortical insufficiency management. However, the introduction of continuous subcutaneous hydrocortisone infusion (CSHI) shows great potential for advancing the management of adrenocortical insufficiency. It resembles the circadian rhythm of physiological cortisol secretion and was shown to have a promising outcome in terms of quality of life (QOL) and clinical outcomes in the literature. We conducted a systematic search strategy including MEDLINE, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and the online trials registers at ClinicalTrials.gov without geographic restrictions. Research investigations where self-reported quality of life (QOL) was assessed as a variable in adult individuals with confirmed adrenal disease, treated by CSHI, and results were presented in English. All articles included were published between 2014 and 2023, even though we had no timeframe limitations in our inclusion criteria. A total of six studies were included, with 63 subjects enrolled, and the average age was 40 years, a study showed a significant reduction in the average total daily dose of HC from 47.5 mg to 31.4 mg on CSHI, while other two studies estimated a reduction in the hospitalization rate due to adrenal crisis from 2.6 to 1.3 admissions per year on CSHI. Most of the studies on subjective well-being and quality of life have shown significant improvement. Overall, CSHI shows great potential as a treatment method for Adrenal insufficiency. It improves the quality of life and lowers hospitalization rates, resulting in increased patient satisfaction and acceptance. Additional comprehensive research is necessary to strengthen these discoveries, gain a deeper understanding of the effectiveness and safety of this treatment approach, and provide guidance for medical practitioners.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could low prolactin levels after radiotherapy predict the onset of hypopituitarism? 放疗后催乳素水平低能否预测垂体功能减退症的发生？

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2024-08-22 DOI: 10.1007/s11154-024-09900-1

Chiara Mele, Stella Pigni, Marina Caputo, Maria Francesca Birtolo, Carola Ciamparini, Gherardo Mazziotti, Andrea Gerardo Antonio Lania, Paolo Marzullo, Flavia Prodam, Gianluca Aimaretti

{"title":"Could low prolactin levels after radiotherapy predict the onset of hypopituitarism?","authors":"Chiara Mele, Stella Pigni, Marina Caputo, Maria Francesca Birtolo, Carola Ciamparini, Gherardo Mazziotti, Andrea Gerardo Antonio Lania, Paolo Marzullo, Flavia Prodam, Gianluca Aimaretti","doi":"10.1007/s11154-024-09900-1","DOIUrl":"https://doi.org/10.1007/s11154-024-09900-1","url":null,"abstract":"Both local and external cranial radiotherapy (RT) can induce neurotoxicity and vascular damage of the hypothalamic-pituitary area, which can promote neuroendocrine alterations. While anterior pituitary insufficiency after RT has been extensively characterized, data on the effect of RT on prolactin (PRL) secretion are limited and heterogeneous, with different patterns of PRL behavior described in the literature. A progressive decline in PRL levels, reflecting a time-dependent, slowly evolving radiation-induced damage to the pituitary lactotroph cells has been reported. To date, the association between hypopituitarism and hypoprolactinemia in patients undergoing RT has not yet been fully investigated. The few available data suggest that lower PRL levels can predict an extent damage of the pituitary tissue and a higher degree of hypothalamic dysfunction. However, most studies on the effect of RT on pituitary function do not properly assess PRL secretion, as PRL deficiency is usually detected as part of hypopituitarism and not systematically investigated as an isolated disorder, which may lead to an underestimation of hypoprolactinemia after RT. In addition, the often-inadequate follow-up over a long period of time may contribute to the non-recognition of PRL deficiency after RT. Considering that hypoprolactinemia is associated with various metabolic complications, there is a need to define appropriate diagnostic and management criteria. Therefore, hypoprolactinemia should enter in the clinical investigation of patients at risk for hypopituitarism, mainly in those patients who underwent RT.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy. 糖皮质激素替代疗法对垂体疾病患者的影响：个性化替代疗法的新视角

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2024-08-22 DOI: 10.1007/s11154-024-09898-6

Sabrina Chiloiro, Alessandra Vicari, Ginevra Mongelli, Flavia Costanza, Antonella Giampietro, Pier Paolo Mattogno, Liverana Lauretti, Alessandro Olivi, Laura De Marinis, Francesco Doglietto, Antonio Bianchi, Alfredo Pontecorvi

引用次数: 0

Primary hyperparathyroidism: from guidelines to outpatient clinic. 原发性甲状旁腺功能亢进症：从指南到门诊。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2024-08-20 DOI: 10.1007/s11154-024-09899-5

Andrea Palermo, Gaia Tabacco, Polyzois Makras, Guido Zavatta, Pierpaolo Trimboli, Elena Castellano, Maria P Yavropoulou, Anda Mihaela Naciu, Athanasios D Anastasilakis

引用次数: 0

The changing landscape of acromegaly - an epidemiological perspective. 从流行病学角度看渐冻人症的变化。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2024-08-01 Epub Date: 2024-02-10 DOI: 10.1007/s11154-024-09875-z

Christian Rosendal, Mai Christiansen Arlien-Søborg, Eigil Husted Nielsen, Marianne Skovsager Andersen, Claus Larsen Feltoft, Caroline Kistorp, Olaf M Dekkers, Jens Otto Lunde Jørgensen, Jakob Dal

{"title":"The changing landscape of acromegaly - an epidemiological perspective.","authors":"Christian Rosendal, Mai Christiansen Arlien-Søborg, Eigil Husted Nielsen, Marianne Skovsager Andersen, Claus Larsen Feltoft, Caroline Kistorp, Olaf M Dekkers, Jens Otto Lunde Jørgensen, Jakob Dal","doi":"10.1007/s11154-024-09875-z","DOIUrl":"10.1007/s11154-024-09875-z","url":null,"abstract":"Acromegaly is a rare disease and thus challenging to accurately quantify epidemiologically. In this comprehensive literature review, we compare different approaches to studying acromegaly from an epidemiological perspective and describe the temporal evolution of the disease pertaining to epidemiological variables, clinical presentation and mortality. We present updated epidemiological data from the population-based Danish cohort of patients with acromegaly (AcroDEN), along with meta-analyses of existing estimates from around the world.Based on this, we conclude that the incidence, prevalence and age at acromegaly diagnosis are all steadily increasing, but with considerable variation between studies. An increased number of incidental cases may contribute to the increase in incidence and age at diagnosis, respectively. The clinical features at presentation are trending toward a milder disease phenotype at diagnosis, and advances in therapeutic options have reduced the mortality of patients with acromegaly to a level similar to that of the general population. Moreover, the underlying cause of death has shifted from cardiovascular to malignant neoplastic diseases.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139712938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multifaceted and inclusive methodology for the detection of sarcopenia in patients undergoing bariatric surgery: an in-depth analysis of current evidence. 检测减肥手术患者肌肉疏松症的多元包容方法：对现有证据的深入分析。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2024-08-01 Epub Date: 2024-03-01 DOI: 10.1007/s11154-023-09864-8

Eunhye Seo, Yeongkeun Kwon, Ahmad ALRomi, Mohannad Eledreesi, Sungsoo Park

{"title":"A multifaceted and inclusive methodology for the detection of sarcopenia in patients undergoing bariatric surgery: an in-depth analysis of current evidence.","authors":"Eunhye Seo, Yeongkeun Kwon, Ahmad ALRomi, Mohannad Eledreesi, Sungsoo Park","doi":"10.1007/s11154-023-09864-8","DOIUrl":"10.1007/s11154-023-09864-8","url":null,"abstract":"Bariatric surgery is widely recognized as the most effective intervention for obesity and offers benefits beyond weight loss. However, not all patients achieve satisfactory weight loss, balanced changes in body composition, and resolution of comorbidities. Therefore, thorough pre- and postoperative evaluations are important to predict success and minimize adverse effects. More comprehensive assessments require broadening the focus beyond body weight and fat measurements to consider quantitative and qualitative evaluations of muscles. Introducing the concept of sarcopenia is useful for assessing the degradative and pathological changes in muscles associated with cardiometabolic function, physical performance, and other obesity-related comorbidities in patients undergoing bariatric surgery. However, there is currently no consensus or definition regarding the research and clinical use of sarcopenia in patients undergoing bariatric surgery. Therefore, this review aimed to define the concept of sarcopenia applicable to patients undergoing bariatric surgery, based on the consensus reached for sarcopenia in the general population. We also discuss the methods and significance of measuring muscle mass, quality, and strength, which are key variables requiring a comprehensive assessment.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inadequate linear catch-up growth in children born small for gestational age: Influencing factors and underlying mechanisms. 胎龄不足新生儿线性追赶生长不足：影响因素和内在机制。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2024-08-01 Epub Date: 2024-05-20 DOI: 10.1007/s11154-024-09885-x

Anran Tian, Fucheng Meng, Sujuan Li, Yichi Wu, Cai Zhang, Xiaoping Luo

引用次数: 0

Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care. 肝糖原贮积症的内分泌参与：病理生理学和对护理的影响。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2024-08-01 Epub Date: 2024-04-01 DOI: 10.1007/s11154-024-09880-2

Alessandro Rossi, Chiara Simeoli, Rosario Pivonello, Mariacarolina Salerno, Carmen Rosano, Barbara Brunetti, Pietro Strisciuglio, Annamaria Colao, Giancarlo Parenti, Daniela Melis, Terry G J Derks

{"title":"Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care.","authors":"Alessandro Rossi, Chiara Simeoli, Rosario Pivonello, Mariacarolina Salerno, Carmen Rosano, Barbara Brunetti, Pietro Strisciuglio, Annamaria Colao, Giancarlo Parenti, Daniela Melis, Terry G J Derks","doi":"10.1007/s11154-024-09880-2","DOIUrl":"10.1007/s11154-024-09880-2","url":null,"abstract":"Hepatic glycogen storage diseases constitute a group of disorders due to defects in the enzymes and transporters involved in glycogen breakdown and synthesis in the liver. Although hypoglycemia and hepatomegaly are the primary manifestations of (most of) hepatic GSDs, involvement of the endocrine system has been reported at multiple levels in individuals with hepatic GSDs. While some endocrine abnormalities (e.g., hypothalamic‑pituitary axis dysfunction in GSD I) can be direct consequence of the genetic defect itself, others (e.g., osteopenia in GSD Ib, insulin-resistance in GSD I and GSD III) may be triggered by the (dietary/medical) treatment. Being aware of the endocrine abnormalities occurring in hepatic GSDs is essential (1) to provide optimized medical care to this group of individuals and (2) to drive research aiming at understanding the disease pathophysiology. In this review, a thorough description of the endocrine manifestations in individuals with hepatic GSDs is presented, including pathophysiological and clinical implications.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11294274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140332014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases). 促炎和抗炎细胞因子是改变儿童肥胖相关代谢疾病（糖尿病和非酒精性脂肪肝）的关键因素。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2024-08-01 Epub Date: 2024-05-06 DOI: 10.1007/s11154-024-09884-y

Amin Ullah, Rajeev K Singla, Zahra Batool, Dan Cao, Bairong Shen

{"title":"Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases).","authors":"Amin Ullah, Rajeev K Singla, Zahra Batool, Dan Cao, Bairong Shen","doi":"10.1007/s11154-024-09884-y","DOIUrl":"10.1007/s11154-024-09884-y","url":null,"abstract":"Childhood obesity is a chronic inflammatory epidemic that affects children worldwide. Obesity affects approximately 1 in 5 children worldwide. Obesity in children can worsen weight gain and raise the risk of obesity-related comorbidities like diabetes and non-alcoholic fatty liver disease (NAFLD). It can also negatively impact the quality of life for these children. Obesity disrupts immune system function, influencing cytokine (interleukins) balance and expression levels, adipokines, and innate and adaptive immune cells. The altered expression of immune system mediators, including interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-17 (IL-17), interleukin-18 (IL-18), transforming growth factor (TGF), tumor necrosis factor (TNF), and others, caused inflammation, progression, and the development of pediatric obesity and linked illnesses such as diabetes and NAFLD. Furthermore, anti-inflammatory cytokines, including interleukin-2 (IL-2), have been shown to have anti-diabetes and IL-1 receptor antagonist (IL-1Ra) anti-diabetic and pro-NAFLFD properties, and interleukin-10 (IL-10) has been shown to have a dual role in managing diabetes and anti-NAFLD. In light of the substantial increase in childhood obesity-associated disorders such as diabetes and NAFLD and the absence of an effective pharmaceutical intervention to inhibit immune modulation factors, it is critical to consider the alteration of immune system components as a preventive and therapeutic approach. Thus, the current review focuses on the most recent information regarding the influence of pro- and anti-inflammatory cytokines (interleukins) and their molecular mechanisms on pediatric obesity-associated disorders (diabetes and NAFLD). Furthermore, we discussed the current therapeutic clinical trials in childhood obesity-associated diseases, diabetes, and NAFLD.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0